Poland· PL-100148159
Maść majerankowa GEMI
A medicinal product containing majoranae unguentum, registered in Poland by GEMIPHARMA Sp. z o.o..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Majoranae unguentum
- Manufacturer
- GEMIPHARMA Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 5
- gtin05909990025886
- gtin05909990025848
- gtin05909990025855
- gtin05909990025862
- gtin05909990025879
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0ef4f95-315e-476c-b623-9b67b998c2dc GET /v1/drugs/c0ef4f95-315e-476c-b623-9b67b998c2dc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Maść",
"source": "urpl",
"strength": "-",
"packaging": "05909990025848 ¦ OTC ¦ 29814\n1 tuba 10 g\n05909990025855 ¦ OTC ¦ Skasowane ¦ 29815\n1 op. 20 g\n05909990025862 ¦ OTC ¦ Skasowane ¦ 29816\n1 op. 30 g\n05909990025879 ¦ OTC ¦ Skasowane ¦ 29817\n1 op. 50 g\n05909990025886 ¦ OTC ¦ Skasowane ¦ 29818\n1 op. 100 g",
"substance": "Majoranae herba extractum (100 g/100 g) 2 cz.",
"common_name": "Majoranae unguentum",
"pl_product_id": "100148159",
"pozwolenie_nr": "IL-2706/LN",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about majoranae unguentum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.